Trial Profile

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Indusatumab vedotin (Primary)
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Sponsors Takeda Oncology

Most Recent Events

11 Feb 2017 Results of interim analysis at the end of stage 1 of the trial published in the Investigational New Drugs.
20 Apr 2016 Interim results (n=36) presented at the 107th Annual Meeting of the American Association for Cancer Research
04 Mar 2016 There is discrepancy in the status among different EudraCT countries. I have kept the status as per NCT.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com